STORM Therapeutics
Develops and advances therapeutic drug candidates for cancer, now progressing a lead program into Phase 2 clinical trials after a $56M Series C financing.
Overview
STORM Therapeutics is a clinical-stage biotechnology company developing therapeutics for oncology and advancing a lead cancer drug into Phase 2 testing. The company focuses on translating early clinical and preclinical research into mid-stage trials targeting cancer patients and healthcare providers addressing unmet oncology needs. In April 2026 STORM closed a $56M Series C led by M Ventures with participation from Pfizer Ventures to fund initiation of the Phase 2 programme. This is the company’s only disclosed round, bringing total known funding to $56M and providing capital to support next-stage clinical development and potential strategic partnerships.
Funding History
STORM Therapeutics raises $56M from M Ventures, Pfizer Ventures to start Phase 2 trial for cancer drug
Frequently Asked Questions
- How much has STORM Therapeutics raised in total?
- STORM Therapeutics has raised a total of $56M across 1 funding round.
- Who are STORM Therapeutics's investors?
- STORM Therapeutics's investors include Undisclosed.
- What does STORM Therapeutics do?
- STORM Therapeutics is a clinical-stage biotechnology company developing therapeutics for oncology and advancing a lead cancer drug into Phase 2 testing. The company focuses on translating early clinical and preclinical research into mid-stage trials targeting cancer patients and healthcare providers addressing unmet oncology needs. In April 2026 STORM closed a $56M Series C led by M Ventures with participation from Pfizer Ventures to fund initiation of the Phase 2 programme. This is the company’s only disclosed round, bringing total known funding to $56M and providing capital to support next-stage clinical development and potential strategic partnerships.
- Where is STORM Therapeutics headquartered?
- STORM Therapeutics is headquartered in San Francisco, CA.
Investors
Related Insights
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
The AI Healthcare sector is one of the most dynamic areas of AI investment in 2026. This report profiles the top-funded startups in the space, their investors, and the market dynamics driving growth.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.